HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis.

Abstract
Responsiveness to methotrexate (MTX), the "anchor drug" for treating rheumatoid arthritis (RA), varies among individual patients. In this study we investigated the effects of folate transporter gene expression levels on disease activity among 56 Japanese patients with RA who were undergoing MTX therapy. We also assessed gene expression levels for 15 healthy control subjects. The mRNA expression levels of reduced folate carrier 1 (RFC1) and proton-coupled folate transporter (PCFT) in PBMCs from these patients and controls were determined using real-time quantitative polymerase chain reaction (PCR). Compared with PCFT, there were large individual differences in RFC1 mRNA expression levels in both RA patients and healthy controls. RFC1 mRNA expression levels and RA disease activity scores were significantly negatively correlated, as disease activity scores were lower for patients with higher RFC1 mRNA expression levels. However, RFC1 mRNA levels were not correlated with MTX doses. Thus, the clinical efficacy of MTX for Japanese RA patients was associated with the expression level of a folate transporter gene. Increased RFC1 expression may increase MTX uptake by immune cells, such as lymphocytes, and as a result, RA disease activity would be reduced.
AuthorsYui Tazoe, Hideki Hayashi, Seiji Tsuboi, Tomone Shioura, Taiji Matsuyama, Hiroshi Yamada, Keita Hirai, Daiki Tsuji, Kazuyuki Inoue, Tadashi Sugiyama, Kunihiko Itoh
JournalDrug metabolism and pharmacokinetics (Drug Metab Pharmacokinet) Vol. 30 Issue 3 Pg. 227-30 (Jun 2015) ISSN: 1880-0920 [Electronic] England
PMID26003891 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Antirheumatic Agents
  • Membrane Transport Proteins
  • Proton-Coupled Folate Transporter
  • SLC19A2 protein, human
  • SLC46A1 protein, human
  • Methotrexate
Topics
  • Adult
  • Aged
  • Antirheumatic Agents (blood, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy, genetics)
  • Case-Control Studies
  • Female
  • Gene Expression
  • Healthy Volunteers
  • Humans
  • Leukocytes, Mononuclear (metabolism)
  • Male
  • Membrane Transport Proteins (genetics)
  • Methotrexate (blood, therapeutic use)
  • Middle Aged
  • Proton-Coupled Folate Transporter (genetics)
  • Real-Time Polymerase Chain Reaction
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: